02.25.15
Takeda Pharmaceutical Co. Ltd. has opened its new office in Biopolis, Singapore. The expanded space will consolidate Singapore operations and serve as the Emerging Markets Business Unit headquarters, Takeda’s Development Center Asia, and the company’s Vaccine Business Unit.
"Our patients are the core of what we do at Takeda. Our new space in Singapore will allow us to more quickly address evolving market needs throughout the rapidly growing Emerging Markets, including Asia-Pacific," said Giles Platford, president, Emerging Markets Business Unit. "It gives us close-to-door access to important market information that will help accelerate the development of medicines needed for battling regional and global health issues."
The decision to relocate the central hub of its Emerging Markets Business Unit is part of its long-term growth strategy in the region. Takeda has had a presence in Asia-Pacific for more than 50 years, and entered Singapore in 2008. Operations in the region include 1,700 staff in 10 countries.
The Vaccine Business Unit based in Singapore has a lab for analytics and development of vaccines to protect against important infectious diseases in the region. One vaccine targets dengue fever and will soon enter Phase III trials. Takeda's Development function is responsible for clinical studies across 12 countries in Asia, supporting clinical activities for compounds in Takeda's key therapeutic areas.
"Our patients are the core of what we do at Takeda. Our new space in Singapore will allow us to more quickly address evolving market needs throughout the rapidly growing Emerging Markets, including Asia-Pacific," said Giles Platford, president, Emerging Markets Business Unit. "It gives us close-to-door access to important market information that will help accelerate the development of medicines needed for battling regional and global health issues."
The decision to relocate the central hub of its Emerging Markets Business Unit is part of its long-term growth strategy in the region. Takeda has had a presence in Asia-Pacific for more than 50 years, and entered Singapore in 2008. Operations in the region include 1,700 staff in 10 countries.
The Vaccine Business Unit based in Singapore has a lab for analytics and development of vaccines to protect against important infectious diseases in the region. One vaccine targets dengue fever and will soon enter Phase III trials. Takeda's Development function is responsible for clinical studies across 12 countries in Asia, supporting clinical activities for compounds in Takeda's key therapeutic areas.